These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12483101)

  • 1. Health economics, economic evaluation, and glaucoma.
    Kobelt G
    J Glaucoma; 2002 Dec; 11(6):531-9. PubMed ID: 12483101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic considerations of the diagnosis and management for glaucoma in the developed world.
    Tuulonen A
    Curr Opin Ophthalmol; 2011 Mar; 22(2):102-9. PubMed ID: 21192264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health Economic Analysis in Glaucoma.
    Park I; Gale J; Skalicky SE
    J Glaucoma; 2020 Apr; 29(4):304-311. PubMed ID: 32053550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis and health policy.
    Torgerson DJ
    Nestle Nutr Workshop Ser Clin Perform Programme; 2009; 12():95-104. PubMed ID: 19858689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term medical management of primary open-angle glaucoma and ocular hypertension in the UK: optimizing cost-effectiveness and clinic resources by minimizing therapy switches.
    Orme M; Collins S; Loftus J
    J Glaucoma; 2012 Sep; 21(7):433-49. PubMed ID: 21677590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The economic implications of glaucoma: a literature review.
    Schmier JK; Halpern MT; Jones ML
    Pharmacoeconomics; 2007; 25(4):287-308. PubMed ID: 17402803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany.
    Kobelt G; Jönsson L; Gerdtham U; Krieglstein GK
    Graefes Arch Clin Exp Ophthalmol; 1998 Nov; 236(11):811-21. PubMed ID: 9825256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Economic Burden of Childhood Glaucoma.
    Liu D; Huang L; Mukkamala L; Khouri AS
    J Glaucoma; 2016 Oct; 25(10):790-797. PubMed ID: 26950576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of resource utilization in the treatment of open-angle glaucoma between two cities in Finland: is more better?
    Hagman J
    Acta Ophthalmol; 2013 May; 91 Thesis 3():1-47. PubMed ID: 23621767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health Economics as Rhetoric: The Limited Impact of Health Economics on Funding Decisions in Four European Countries.
    Franken M; Heintz E; Gerber-Grote A; Raftery J
    Value Health; 2016 Dec; 19(8):951-956. PubMed ID: 27987645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostaglandin analogues for the treatment of glaucoma and ocular hypertension: a systematic review of economic evidence.
    Orme M; Boler A
    Pharmacoeconomics; 2006; 24(8):743-50. PubMed ID: 16898845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling the lifetime economic consequences of glaucoma in France.
    Philippe Nordmann J; Lafuma A; Berdeaux G
    J Med Econ; 2009 Mar; 12(1):9-16. PubMed ID: 19450060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of health care and policymaking.
    Johannesson M
    Health Policy; 1995 Sep; 33(3):179-90. PubMed ID: 10145120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden.
    Lindblom B; Nordmann JP; Sellem E; Chen E; Gold R; Polland W; Williamson W; Buchholz P; Walt JG; Groleau D; Curry A; Evans SJ
    Acta Ophthalmol Scand; 2006 Feb; 84(1):74-83. PubMed ID: 16445443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma.
    Lee PP; Walt JG; Doyle JJ; Kotak SV; Evans SJ; Budenz DL; Chen PP; Coleman AL; Feldman RM; Jampel HD; Katz LJ; Mills RP; Myers JS; Noecker RJ; Piltz-Seymour JR; Ritch RR; Schacknow PN; Serle JB; Trick GL
    Arch Ophthalmol; 2006 Jan; 124(1):12-9. PubMed ID: 16401779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methods for economic evaluation alongside a multicentre trial in developing countries: a case study from the WHO Antenatal Care Randomised Controlled Trial.
    Mugford M; Hutton G; Fox-Rushby J
    Paediatr Perinat Epidemiol; 1998 Oct; 12 Suppl 2():75-97. PubMed ID: 9805724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An assessment of the health and economic burdens of glaucoma.
    Varma R; Lee PP; Goldberg I; Kotak S
    Am J Ophthalmol; 2011 Oct; 152(4):515-22. PubMed ID: 21961848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Core and comprehensive health care services: 4. Economic issues.
    Wyman M; Feeley J; Brimacombe G; Doucette K
    CMAJ; 1995 May; 152(10):1601-4. PubMed ID: 7743446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glaucoma in the United States and europe: predicting costs and surgical rates based upon stage of disease.
    Lee PP; Kelly SP; Mills RP; Traverso CE; Walt JG; Doyle JJ; Katz LM; Siegartel LR;
    J Glaucoma; 2007 Aug; 16(5):471-8. PubMed ID: 17700290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations in developing model-based economic evaluations of glaucoma treatment.
    Althin R; Grima DT; Dhawan R; Bernard LM
    J Glaucoma; 2006 Dec; 15(6):541-7. PubMed ID: 17106369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.